Advertisement

 

 

Treatment Considerations in Pulmonary Coccidioidomycosis.

Treatment Considerations in Pulmonary Coccidioidomycosis.
Author Information (click to view)

Hartmann CA, Aye WT, Blair JE,


Hartmann CA, Aye WT, Blair JE, (click to view)

Hartmann CA, Aye WT, Blair JE,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of respiratory medicine 2016 9 16()

Abstract

Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in special populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors.

Submit a Comment

Your email address will not be published. Required fields are marked *

seven + 17 =

[ HIDE/SHOW ]